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Prognosis
SalivaOral cancer features high rates of mortality and morbidity, and is in dire need for new approaches. In the
present study we analyzed 18 kDa translocator protein (TSPO) expression in oral (tongue) cancer tumors by
immunohistochemistry. We also assayed TSPO binding in human tongue cancer cell lines and in the cellular
fraction of saliva from tongue cancer patients, heavy cigarette smokers, and non-smoking healthy people as
controls. Concurrently, TSPO protein levels, cell viability, mitochondrial membrane potential (Δψm), and
general protein levels were analyzed. TSPO expression could be signiﬁcantly enhanced in oral cancer tumors,
compared to unaffected adjacent tissue. We also found that ﬁve-year survival probability dropped from 65%
in patients with TSPO negative tumors to 7% in patients with highly expressed TSPO (p<0.001). TSPO
binding capacity was also pronounced in the human oral cancer cell lines SCC-25 and SCC-15 (3133±
643 fmol/mg protein and 6956±549 fmol/mg protein, respectively). Binding decreased by 56% and 72%, in
the SCC-25 and SCC-15 cell lines, respectively (p<0.05) following CS exposure in cell culture. In the cellular
fraction of saliva of heavy smokers TSPO binding was lower than in non-smokers (by 53%, p<0.05). Also the
cellular fraction of saliva exposed to CS in vitro showed decreased TSPO binding compared to unexposed
saliva (by 30%, p<0.001). Interestingly, oral cancer patients also displayed signiﬁcantly lower TSPO binding
in the cellular fraction of saliva compared to healthy controls (by 40%, p<0.01). Our results suggest that low
TSPO binding found in the cellular fraction of saliva may depend on genetic background as well as result from
exposure to CS. We suggest that this may be related to a predisposition for occurrence of oral cancer.t the Department of Molecular
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Oral cancer, which is induced primarily by cigarette smoke (CS), is
the sixth most common malignancy. The carcinogenetic effect of
cigarette smoke is enhanced by salivary modulation [1]. Oral cancer is
characterized by a poor 5-year survival rate of only 50% and a high
rate of morbidity, which have not changed signiﬁcantly in the past
half-century [2–4]; thus, a better understanding of the biological
nature of this aggressive disease is mandatory. Accordingly, we
examined a potential novel player in the ﬁeld of oral cancer, the
translocator protein (18 kDa) (TSPO). The TSPO, which was previ-ously called peripheral-type benzodiazepine receptor (PBR), was ﬁrst
identiﬁed in 1977 as a diazepam binding site outside the brain [5].
This led to its assignment as ‘peripheral-type’ benzodiazepine
receptor (PBR), to distinguish it from the central benzodiazepine
receptor (CBR). While the CBR is primarily located on cell membranes
of neurons in the CNS, the TSPO's location is mostly on mitochondrial
membranes in various cell types. The TSPO has been detected in
various densities in themajority of tissues tested [6,7]. TSPO is located
mainly in the outer mitochondrial membrane and is closely associated
with the mitochondrial permeability transition pore (MPTP). In-
creased binding levels of TSPO have been observed in various human
cancers [6,8–13]. The expression and binding levels of TSPO have been
found to correlate with the tumorigenicity of various cancer cell lines
[14]. Weisinger et al. [15] induced TSPO underexpression by using the
stable anti-sense knockout approach in the MA-10 Leydig cell line.
The resultant clones demonstrated increased tumorigenicity, using
both in vitro (loss of contact inhibition and growth in soft agar) and in
vivo (increased mortality after back grafting into isogenic mice)
assays. Other studies applying TSPO knockdown by genetic
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well as application of TSPO speciﬁc ligands, showed that the TSPO
plays an important role in the induction of all the aspects of the
mitochondrial apoptosis pathway, as well as necrosis [16–20].
In the current study we used 3 models to study the potential
pathogenic role of TSPO in oral cancer. These models included oral
cancer tissues, oral cancer cell lines, and the cellular fraction of saliva
of oral cancer patients. The salivary analysis was also conducted in
non-smoking healthy individuals as well as in heavy smokers, both in
vivo and in vitro.
2. Patients and methods
2.1. Experimental design
The in vivo part of the study was based on an analysis of 69
patients (33 males and 36 females aged 65.7±15.2 years) with
tongue cancer whose archival parafﬁn-embedded pathological mate-
rial was available for immunohistochemical staining analysis of TSPO.
In 41 cases we studied the TSPO staining levels together with those of
Skp2 and p27 proteins. The analysis was performed as previously
described [21]. Seventeen patients were diagnosed with stage 1
disease; 27 with stage 2; 10 with stage 3; and 15 with stage 4. All
patients had their tumors resected within 1–2 weeks after diagnosis,
followed by radiation therapy to the head and neck region for patients
at stages 2–4, with a mean dose of 60 Gy. The study protocol was
approved by the Institutional Review Board. Clinical data included
histopathological grading, tumor-node-metastasis (TNM) staging,
and status at the end of the study (alive or deceased).
In the in vitro part of the study we analyzed the TSPO binding and
expression in the oral cancer cell lines, SCC-25 and SCC-15, purchased
from the American Type Culture Collection (ATCC, Manassas, VA,
USA). In addition, the cellular fraction of saliva from oral cancer
patients was analyzed, as well as from a group of cigarette smokers,
and their control groups matching in age and gender. For the oral
cancer patient's analysis, whole saliva was collected from a group of
otherwise-healthy, consenting oral cancer patients who were com-
pared to a control group of healthy individuals who matched in age
and gender. None of the patients had a history of smoking, none of
alcohol-drinking, and none had a history of oral pre-malignant lesions
or any other oral disease. All cancer lesions were located at the lateral
aspect of the mobile tongue. A similar approach was applied
previously to groups of oral cancer patients whose rate of smoking
habits was very low [22]. The saliva was collected prior to the
administration of the therapy, and frozen at −70 °C before further
processing and analysis.
For in vivo salivary analysis of a group of heavy smokers (over 20
cigarettes daily for at least 10 years) all smokers were asked to
schedule the smoking of one of their cigarettes immediately prior to
saliva collection, to reduce potential variability that may otherwise be
introduced by the various time spans between exposure to cigarette
smoke and saliva collections, as previously described [23]. The
smokers were comparedwith a control group of healthy non-smoking
individuals. Following collection and storage, the salivary samples
were subjected to cell viability observations, TSPO binding assays,
Western blot analysis, and protein level determination as previously
described [24–27]. It has been reported previously that saliva may
contain various types of cells, including exfoliated epithelial mucosal
cells, [22,28–30]. We also conducted an in vitro salivary analysis in
which the cellular fractions of saliva samples collected from healthy
non-smoking volunteers (age range 20–65 years; 60% females and
40% males) were subjected to TSPO binding assay following exposure
to cigarette smoke (14 mg tar and 0.9 mg nicotine per cigarette), as
previously described [1]. Brieﬂy, a cigarette was combined with a
vacuum system to enable the inhalation of gas-phase cigarette smoke
into a sealed apparatus containing the salivary samples (whole saliva)[1]. Previous studies have shown, by measuring the NO2-concentra-
tions in the media, that the time of exposure to the smoke correlates
directly with the level of exposure to cigarette smoke [31–33]. Using
the same system we also exposed oral cancer cell lines to cigarette
smoke. Using these various models allowed studying oral cancer both
at the tissue level (specimens of tumors) and at the cellular level (cells
in saliva and oral cancer cell lines in cell culture medium).
2.2. Immunohistochemical analysis and Western blot
The preparation and speciﬁcity of the antiserum against TSPOwere
described previously [17,18,20]. This antiserum was used for the
immunohistochemistry and Western blot analysis of the present
study. Western blot analysis with this antiserum was performed as
described in detail previously [17,18,20]. Labeling of β-actin was used
as a loading control. Labeling for the 32 kDa voltage dependent anion
channel (VDAC) was done as routinely performed in our laboratory
(e.g. [17,20,27]) as it is a protein closely associated with the TSPO.
For immunohistochemical staining of oral cancer specimens and
control tissue, ﬁve micron sections were deparafﬁnized with xylene
and rehydrated in a series of ethanol. Endogenous peroxidase was
blocked by 3% hydrogen peroxide in methanol for 20 min. For epitope
retrieval, slides were heated in a microwave oven at 92 °C for 20 min
in a Tris-EDTA-buffer pH 8.0. After cooling, slides were washed in
distilled water and then in phosphate-buffered saline (pH 7.4). Slides
were incubated overnight at 4 °C with the primary antiserum directed
against TSPO diluted 1:100. Stainingwas completedwith a Histostain-
Plus kit (Zymed laboratories, CA). Color reaction product was
developed with aminoethylcarbazole as the chromogen. All sections
were counterstained with hematoxylin, dehydrated, and cover
slipped. Incubations with phosphate-buffered saline containing 1%
bovine serum albumin instead of the primary antibody were used as
negative controls. Skp2 and p27 antisera were applied with similar
immunostaining procedures, as described previously [21,34].
Staining intensity was examined microscopically, double blind, as
neither the person examining the sections nor the person providing
the sections to the examiner knew the patient origin of the samples.
Weak cytoplasmic staining intensity for TSPO of tumor cells was
graded <1 (weak). Weak staining meant that less than 50% of tumor
cells were stained. Moderate to strong cytoplasmic staining of tumor
cells was graded >1 (moderate–strong). In all cases of moderate to
strong staining for TSPO more than 50% of tumor cells were stained.
Skp2 and p27 staining intensity was determined as described
previously i.e. at least 500 tumor cell nuclei were counted and from
this population the percentage of Skp2 and p27 positive cells was
calculated [21,34].
2.3. Cell viability
Cell viability was determined in saliva samples using the Trypan
Blue exclusion test. Following treatment, saliva samples were
centrifuged at 800 ×g for 10 min and the pellet containing the
cellular fraction was suspended in phosphate-buffered saline (PBS).
Cell counting was performed using an inverted microscope and a
hemocytometer. Both viable and non-viable cells were counted and
the percentage of viable cells was calculated from the total number of
cells.
2.4. Mitochondrial transmembrane potential analysis
The speciﬁc stain JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-
benzimidazolylcarbocyanine iodide) was used to assay changes in the
Δψm following exposure oral cancer cell lines to cigarette smoke, as
described in detail previously [17,20,35]. Brieﬂy, samples of conﬂuent
cells were collected and centrifuged at 1200 ×g for 10 min. Cell pellets
were re-suspended in 1 µg/ml JC-1 solution in PBS and incubated at
Fig. 1. TSPO labeling in oral cancer tumors. Cytoplasmatic, slightly granular staining
TSPO (arrows) of well to moderately differentiated carcinoma (A). Cytoplasmatic,
slightly granular staining TSPO (arrows) of moderately to poorly differentiated
carcinoma (B). Non-carcinogenic neighboring tissue did not show TSPO labeling (not
shown).
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centrifuged at 1200 ×g for 10 min, and re-suspended in 0.5 ml PBS.
Then, the cell suspensions were transferred into 5 ml FALCON® FACS
tubes and analyzed with the ﬂow cytometer using CellQuest software.
2.5. TSPO binding analysis of saliva and oral cancer cells
Assays of [3H] PK 11195 binding to membranes of the SCC-15 and
SCC-25 cells for Scatchard analysis were conducted, according to
methods described previously [14,16,25]. The reaction mixture
contained 400 µl of the homogenized samples and 25 µl of [3H]PK
11195 (ﬁnal concentration of 0.2–6 nM), in the absence (total
binding) or in the presence (non-speciﬁc binding) of 10 µM unlabeled
PK 11195. After 80 min incubation at 4 °C, the samples were ﬁltered
through Whatman CF/C ﬁlters using a vacuum system, washed three
times with 4 ml of 5 mM ice cold phosphate buffer and placed in vials
containing 4 ml of CytoScint™ (MP Biomedicals, Costa Mesa, CA).
Radioactivity was counted after 12 h with a liquid scintillation
analyzer. Speciﬁc binding was obtained by subtracting non-speciﬁc
binding from total binding. The maximal binding capacity (Bmax) and
equilibrium dissociation constant (Kd), were calculated from the
saturation curve of [3H]PK 11195 binding, using Scatchard analysis.
For binding analysis of the cellular fraction of saliva, saliva samples
were thawed and immediately centrifuged (800 ×g, 10 min, 4 °C).
The pellet, containing cells present in the saliva, was suspended in ice
cold PBS, and then homogenized using a Kinematika Polytron
(Luzerne, Switzerland) (setting 6) for 10 s. Total protein amount
was determined, according to Bradford et al. [24]. TSPO binding assays
of the saliva were conducted at concentrations of 6 nM and 12 nM of
[3H] PK 11195.
2.6. Statistical analysis
For categorical variables, frequencies and percentages were
calculated. Distributions for categorical variables were compared
and analyzed by the Fisher–Irwin exact test (small sample). For
continuous variables, ranges, means, standard deviation, and standard
error were calculated. The results of continuous variables between
subgroups of patients were compared and analyzed by one way
analysis of variance. The “Kaplan Meier estimate” was used to
calculate the probability of survival rates as a function of time. The
“Log Rank test” was used to compare between survival curves.
p<0.05 was taken as indicating statistically signiﬁcant differences.
3. Results
3.1. TSPO levels in tongue cancer samples and clinical characteristics
Of the 69 oral cancer patients analyzed, oral tumor tissue of 12
patients (18%) stained negatively (=0) for TSPO while the other 57
patients (82%) the oral tumor tissue stained positively. The TSPO
positive group was further categorized according to the intensity of
staining: weak staining (<1) was found in 52% (36/69) of the
specimens and moderate to strong staining (>1) in 30% (21/69). The
TSPO staining was cytoplasmatic and slightly granular in the tumor
tissue (Fig. 1), while the adjacent, normal-looking tissue was not
stained by the anti-TSPO antibody (not shown), thus serving as
internal controls. TSPO immunostaining was not signiﬁcantly differ-
ent between males and females nor was it signiﬁcantly affected by
age. Neither did the TSPO level signiﬁcantly correlate with the grading
(Fig. 1) nor with the T, N or M values.
3.2. Prognostic value of TSPO for oral cancer
In order to determine the prognostic value of TSPO for tongue
cancer patients, we analyzed their cumulative survival according toTSPO expression levels. The intensity of TSPO staining correlated
strongly with patient mortality. While 65% of the patients negative for
TSPO and 57% of the patients with low (<1) TSPO levels in the tongue
tumor were still alive at 60 months, only 7% of the patients with
moderate to strong (>1) TSPO labeling of the tongue tumor tissue
survived the 60 month period (p<0.001) (Fig. 2).
3.3. Correlations between TSPO, Skp2 and p27 expression levels in oral
cancer tissue
Oral tumor TSPO staining levels correlated negatively with Skp2
levels and positively with p27. In particular, the mean Skp2 staining
level of the TSPO positive (>0) specimens was signiﬁcantly lower
than that of the TSPO negative specimens (=0), 14.5±2.1% (in 32
patients) vs. 21.5±4.7% (in 7 patients), respectively (p=0.05)
(Table 1A). In contrast, the mean p27 staining level of the TSPO
positive specimens was signiﬁcantly higher than that of the TSPO
negative specimens, 39±2.3% (in 34 patients) vs. 27±4.2% (in 7
patients), respectively (p<0.05), (Table 1B).
3.4. TSPO in the SCC-25 and SCC-15 cells
We applied Western blot to determine whether TSPO is present in
SCC-25 and SCC-15 cells. TSPO indeed are expressed in these human
oral cancer cells. A representative Western blot of SCC-25 cells is
presented in Fig. 3.
Fig. 2. Correlation between TSPO levels in oral cancer tissue and survival rates.
Cumulative survival rate and TSPO expression (‘0’ vs. ‘<1’ vs. ‘>1’) (n=69). The
probability of survival of patients with TSPO level (=0) at 60 months was 65% while
the probability of survival of patients with TSPO level (>1) at 60 months was 7% only.
***p<0.001 for >1 vs. =0.
Fig. 3. Protein expression of TSPO, VDAC, and beta-actin in oral cancer cell lines. A
representative Western blot analysis of TSPO, VDAC and β actin proteins in the SCC-25
cell line growing under normal physiological conditions.
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SCC-15 oral cancer cell lines
Binding assays with [3H]PK 11195 showed Bmax and Kd values for
the SCC-25 cells of 3133±643 fmol/mg protein and 5.7±2.0 nM,
respectively (mean±SD, n=7). The Bmax and Kd values of the SCC-15
cells were 6956±549 fmol/mg protein and 5.9±4.6 nM, respectively
(mean±SD, n=16). Non-speciﬁc binding of [3H]PK 11195 to human
oral cancer cells was one third of the total binding. Representative
Scatchard analysis of saturation curves of [3H]PK 11195 speciﬁc
binding to TSPO in human oral cancer cell lines SCC-25 and SCC-15 is
presented in Fig. 4.
3.6. TSPO binding and protein concentration following exposure of
SCC-25 and SCC-15 cells to cigarette smoke
With binding assays of SCC-25 cells that were exposed to CS for
90 min, using [3H]PK 11195 as a radioligand (ﬁnal concentrations
3 nMand6 nM)we founda signiﬁcant decrease of 72% in TSPObinding
at the concentration of 3 nM [3H]PK 11195 in the CS-exposed cells, as
compared to controls (n=6; p=0.01; data not shown). Similarly, the
mean TSPO binding at a ﬁnal concentration of 6 nMwas lower by 56%
in the CS-exposed cells (n=6; p=0.05; data not shown). Using a
concentration of 3 nM [3H]PK 11195 in CS-exposed SCC-15 cells, we
also found a signiﬁcant decrease of 64% in TSPObinding as compared to
controls (data not shown). Total protein concentrations in SCC-25 and
SCC-15 cells exposed to cigarette smoke (CS) for 90 min did not differ
from controls, as measured by the method of Bradford et al. [24].Table 1
The percentage of Skp2 labeled cells is signiﬁcantly lower in tongue cancer specimens
with enhanced TSPO levels (A), while the percentage of p27 levels is signiﬁcantly
higher in tongue cancer specimens with enhanced TSPO levels (B).
TSPO level 0 >0
A. TSPO and Skp2 staining levels in tongue cancer specimens
Number of oral cancer patients 7 32
Mean % of Skp2 labeled cells 21.5 14.5*
SE 4.77 2.10
*p=0.05
B. TSPO and p27 staining levels in tongue cancer specimens
TSPO level 0 >0
Number of oral cancer patients 7 34
Mean % of p27 labeled cells 27.0 39.0*
SE 4.2 2.3
*p<0.053.7. Collapse of the mitochondrial transmembrane potential in SCC-25
cells exposed to cigarette smoke
The mitochondrial potential stability assays as assayed in SCC-25
cells showed that cigarette smoke caused collapse of the mitochon-
drial membrane potential (Δψm) in 80% of the cells, which present a
signiﬁcant increase from to control (Fig. 5). Collapse of the Δψm can
lead to cell death, including apoptosis [17,20].Fig. 4. TSPO binding characteristics in oral cancer cell lines. Scatchard plots (A,B) of [3H]
PK 11195 (0.2–6 nM ﬁnal concentration) binding to SCC-25 human oral cancer cell line
(panels A and B respectively) and to SCC-15 human oral cancer cell line, (n=16).
Explanation of abbreviations: B = concentration of Bound ligand, B/F = concentration
of Bound ligand over concentration of Free ligand.
Fig. 5. Collapse of the mitochondrial membrane potential after exposure of SCC-25 cells
to cigarette smoke. Exposure of SCC-25 oral cancer cells in culture to cigarette smoke
(CS) causes collapse of Δψm in the majority of the cells, as indicated by unpolymerized
JC-1 levels. ***p<0.001 compared to control (n=6).
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of saliva of heavy smokers
Similar to the effects of CS on the TSPO binding in the oral cancer
cell lines, the cellular fraction of saliva from heavy smokers showed
that the mean±SE TSPO binding with the [3H]PK 11195 ligand (at a
ﬁnal concentration of 6 nM) was reduced signiﬁcantly by 53%
(9 smokers), as compared to the control group (16 non-smokers)
(p<0.05) (Fig. 6A). Western blot analyses of TSPO, VDAC and β actin
proteins in the cellular fraction of saliva fromnon-smoking individuals
and smoking individuals, revealed a lower expression of the TSPO and
VDAC proteins in heavy smokers (Fig. 6B). The mean±SE percentage
values of viable salivary cells were found to be similar in both groups,
with 36±4% in control saliva (16 non-smokers) and 37±4% inFig. 6. TSPO binding in saliva of cigarette smokers and non-smokers. (A) Mean±SE [3H]
PK 11195 speciﬁc binding values (ﬁnal concentrations 6 nM) in saliva of non-smoking
individuals (Control, n=16) and heavy smokers (Smokers, n=9) (p<0.05). (B) A
representative Western blot analysis of TSPO, VDAC and β actin proteins in saliva of a
non-smoking individual (termed Non-smoker), and a smoking individual (termed
Smoker).smokers saliva (6 smokers). Also the mean±SE of total protein
concentration in saliva of non-smoking controls (16 non-smokers)
and heavy smokers (9 smokers) were similar, i.e. 0.31±0.08 mg/ml
and 0.44±0.16 mg/ml respectively.
3.9. In vitro analysis of TSPO binding, cell viability, and total protein
levels in saliva exposed to CS
Saliva samples which had been collected from healthy non-
smoking volunteers were exposed to CS in vitro and then the cellular
fraction subjected to TSPO binding analysis. The binding analysis with
a single [3H]PK 11195 (6 nM ﬁnal concentration), in control and CS-
exposed saliva revealed a signiﬁcant 30% reduction of the TSPO
binding (n=34, p<0.001) in response to CS exposure, compared to
sham controls (Fig. 7). Cigarette smoke did not appear to affect cell
viability in saliva. The mean percentage values of viable cells were
found to be similar in both groups, with 32.0±3.8% in control saliva
(n=25) and 36.0±3.5% (n=25) in cigarette smoke-exposed saliva.
The mean total protein concentrations in the cellular fractions from
the control and the cigarette smoke-exposed samples were similar
(data not shown).
3.10. TSPO binding, cell viability, and total protein levels in saliva of oral
cancer patients
We conducted two separate binding experiments on saliva
samples of oral cancer patients and healthy controls, using [3H]PK
11195 as a radioligand. In the ﬁrst experiment we used two
concentrations of [3H]PK 11195 (6 nM and 12 nM), and in the second
experiment we used 6 nM only. In the ﬁrst experiment (Fig. 8) we
compared 13 salivary samples of oral cancer patients with 6 salivary
samples of controls, and found a signiﬁcant 38% decrease in TSPO
binding at the concentration of 6 nM [3H]PK 11195 (p<0.05) in the
cellular fraction of saliva from oral cancer patients, as compared to
controls. Similarly, the mean TSPO binding at a ﬁnal concentration of
12 nMwas signiﬁcantly lower by 41% in the cancer patients (p<0.05)
(Fig. 8). In the second experiment, using 6 nM ﬁnal concentration of
[3H]PK 11195, the decrease in TSPO binding in the cellular fraction
from saliva of oral cancer patients was 40% (n=12 for healthy
controls, n=7 for oral cancer patients, p<0.05).
Viability assays with Trypan blue showed that the mean±SE
percentage values of viable cells were similar in both groups, with
48 ±7% in saliva of controls (n=16) and 40±4% in saliva of oral
cancer patients (n=7). Also the mean±SE total protein concentra-
tion [24] in the cellular fraction of saliva from healthy controlsFig. 7. TSPO binding in saliva exposed to cigarette smoke in vitro. Binding of [3H]PK
11195 (ﬁnal concentration 6 nM) in control saliva and saliva (collected from non-
smoking healthy individuals) exposed in vitro to cigarette smoke. The results are
expressed as mean values±SE (n=34, p<0.001).
Fig. 8. TSPO binding in saliva of oral cancer patients and healthy persons. Mean±SE
[3H]PK 11195 speciﬁc binding values (ﬁnal concentrations 6 nM and 12 nM) in saliva of
healthy individuals (Control, n=6) and oral cancer patients (Cancer, n=13). p<0.05
for both concentrations compared to control.
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0.05 mg/ml and 0.35±0.08 mg/ml, respectively).
4. Discussion
To our knowledge this is the ﬁrst study describing a conspicuous
correlation between enhanced TSPO expression in oral cancer tissue
and reduced patient survival rate. We also found statistically
signiﬁcant correlations between TSPO protein levels and those of
Skp2 and p27. Levels of Skp2 and p27 were previously shown to
correlate with the histopathological grading of oral cancer [21,34].
Interestingly, TSPO binding in the cellular fraction of saliva from oral
cancer patients was lower than in healthy controls. We assume that
TSPO binding in the cellular fraction of saliva relates primarily to
exfoliated epithelial mucosal cells, as this is a constant process in the
GI tract, and we found this to be predominant type of cell present in
saliva [22,23,28–30]. In a separate study we found the morphology of
themajority of the cells in the saliva to be of a stratiﬁed epithelial type
(in press, [36]). Thus, TSPO may present an additional marker for oral
cancer prognosis in the clinical set-up, on the one hand by its
histopathological expression evaluation in oral cancer patients, and
on the other hand by assays of salivary TSPO binding of at risk persons.
The enhanced levels of TSPO in oral cancer tissue correlating with
poor prognosis are in accord with previous studies where TSPO over-
expression has been shown to correlate with tumorigenicity in
various human malignancies such as for example brain, breast, colon,
and prostate cancer [6,8,9,11–14,37]. Experimental studies inducing
down-regulation of TSPO in MA-10 Leydig tumor cells, using anti-
sense TSPO knockdown techniques, resulted in increased tumorige-
nicity in vitro and in vivo [15], and TSPO knockdown in C6 glioma cells
resulted in a 60% reduction of apoptotic rates [16]. Also other studies
applying TSPO knockdown with other techniques to other cancer cell
lines showed reduced apoptotic rates with reduced TSPO levels
[18,20]. Similar effects were obtained with application of the speciﬁc
TSPO ligands PK 11195 and Ro5 4864 [14,17,19,20]. Thus, these
studies in various cancer cell lines, employing various methods of
TSPO knockdown, and various types of TSPO ligands indicate that the
TSPO can serve to activate the mitochondrial apoptosis cascade. In
addition, it was found that the mechanismwhereby TSPO initiates the
mitochondrial apoptosis cascade includes oxidation of cardiolipins i.e.
ROS generation at mitochondrial levels [19,20]. Recently, it was found
that activation of the TSPO affects the activity of the Fo subunit of the
mitochondrial ATPsynthase, i.e. TSPO can modulate the activity of this
Fo proton pump in the inner mitochondrial membrane [37]. We
assume that this modulation of the Fo proton pump presents the
mechanism allowing TSPO to generate ROS for the induction ofcardiolipin oxidation leading to activation of the mitochondrial
apoptosis cascade [19,38]. From these studies it was hypothesized
that enhanced TSPO levels present a mechanism directed to cause
programmed cell death, a mechanism that apparently does not
function to its full potential in established cancers [19,37–39].
In the light of TSPO established pro-apoptotic i.e. anti-carcinogenic
properties, it may be considered puzzling that the over-expression of
TSPO in the oral cancer cases was correlated with reduced survival in
the present study [16–19,39]. It has been postulated that mechanisms
related to the TSPO are defective and thereby prevent TSPO to fully
exert its pro-apoptotic function (i.e. either mechanisms serving to
activate TSPO may be defective, or mechanisms typically activated by
TSPO are defective). For example, caspase activation in C6 cells
appears to be not fully functional [16]. An alternative explanation
postulated here for the present data might be that the over-expressed
TSPO itself in the oral cancer tumors may be of a defective and
malfunctioning nature. A similar mechanistic explanation is often
given for the well known enhanced expression of mutated p53 which
is demonstrated in most human cancers [40]. More studies regarding
actual interactions between causes and progression of oral cancer,
TSPO functions, and apoptosis are needed. It is also well recognized
that careful consideration of parameters and paradigms is needed to
come to generally applicable conclusions regarding the involvement
of TSPO cancer cell proliferation and cell death [18,20,41–44]. It was
found in one study, for example, that both low concentrations and
high concentrations of CoCl2 lead to cell death of brain cancer cells,
however, low concentrations CoCl2 led to reductions in TSPO levels,
while high concentrations of CoCl2 enhanced TSPO levels [20]. Only
application of TSPO knockdown showed that TSPO was required for
apoptosis in this paradigm [20]. Furthermore, while the apoptosis can
be considered an important feature of carcinogenesis, it is also well
known that the TSPO is involved in other important functions, such as
cholesterol transport over the outer mitochondrial membrane and
modulation of steroidogenesis, inﬂammation, and immune response
[39,45].
Analysis of TSPO in the oral cancer cell lines, SCC-25 and SCC-15,
revealed that TSPO is well expressed in these cells. The oral cancer cell
lines were sensitive regarding viability when exposed to cigarette
smoke, in correlations with reductions in TSPO binding. For example,
we found that cigarette smoke causes collapse of the mitochondrial
membrane potential in SCC-25 cells. Regarding cells in saliva,
exposure of salivary samples to cigarette smoke did not appear to
affect viability of cells in these salivary samples, while simultaneously
reductions in TSPO binding were observed. Similarly, oral cancer
patients showed relatively low levels of TSPO in the cellular fraction of
salivary samples, without concomitant effects on cell viability in these
salivary samples. It is not clear why viability of cells in saliva is not
affected by cigarette smoke, while cultured oral cancer cell lines
appear to be very sensitive to cigarette smoke. More detailed studies
are required to resolve these questions.
Our study may be giving an additional lead why cigarette smoke
presents a main inducer of oral cancer as well as lung cancer and
various other cancers [46]. We report here signiﬁcantly reduced TSPO
binding to membrane homogenates prepared from the cellular
fraction of saliva from heavy smokers. Similarly, we found signiﬁ-
cantly reduced TSPO binding to membrane homogenates prepared
from the cellular fraction of saliva of non-smoking oral cancer
patients. One possibility is that low levels of TSPO protein expression
and/or binding, either due to exposure to cigarette smoke, or due to
genetic disposition, as suggested by our salivary assays, renders cells
more sensitive to induction of carcinogenesis (Fig. 9). Previous
studies, applying TSPO knockdown have shown that reduced TSPO
levels (TSPO knockdown) can reduce apoptotic levels, this may
prevent programmed cell death in neoplastic cells [16,18,20]. As we
do not see effects of cell death in salivary samples of heavy smokers
and oral cancer patients, at present we cannot conclude deﬁnitely
Fig. 9. Schematic presentation suggested for the implication of TSPO in the pathogenesis of
oral cancer. Both cigarette smoke and genetic disposition appear to lead to reduced TSPO
binding in the saliva which appears to correlate with an increased susceptibility to tongue
cancer.
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fraction of saliva may potentially contribute to oral cancer tumorige-
nicity. Furthermore, our data presently do not resolve whether
reduced TSPO binding in the cellular fraction of saliva from cigarette
smokers is due to an acute effect of cigarette smoke exposure, or a
long term effect due to the chronic cigarette smoke exposure. More
studies are needed to answer these questions. Furthermore, the
speciﬁc molecular biological mechanism by which cigarette smoke
reduces TSPO binding, as currently shown in the SCC-25 and SCC-15
cells, and salivary cells, is yet to be elucidated. Previous studies have
suggested that oxidative stress can affect the afﬁnity of the TSPO due
to the formation of homomeric TSPO multimers [47], this may be part
of the mechanism whereby cigarette smoke may affect TSPO binding.
A potential role of TSPO in the pathogenesis of oral cancer may
originate from its location at chromosome 22q13.31. QRT-PCR has
shown that speciﬁc region deletion on 22q13 is related to prognosis in
oral cancer. Furthermore, the incidence of loss of heterozygosity
(LOH) at chromosome 22q is high and is associated with the
carcinogenesis of oral cancer [48,49]. Different tumor suppressor
genes related also to oral cancer are located in distinct regions on
chromosome 22q [50]. Possibly, TSPO is part of this family of tumor
suppressor genes.
In summary, our results indicate for the ﬁrst time that increased
TSPO levels in oral cancer tissue may be correlated with oral cancer
mortality prognosis. On the other hand, reductions in TSPO binding in
the cellular fraction of saliva in the oral cavity may contribute to the
occurrence of cancer. This role of salivary TSPO may be based on
induced reductions in the TSPO normal binding and/or protein
expression rendered by inborn defects or by a later exposure to
carcinogens such as those contained in cigarette smoke (Fig. 9). Thus,
our studies suggest that TSPO malfunction may contribute to
carcinogenesis, implying that the TSPO may be targeted as a venue
for treatment of oral cancer. More studies correlating TSPO functions
with oral cancer prognosis and diagnosis are needed. In particular,
causal relationships need to be established in this area.Acknowledgements
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